APA

Schweikert B., Malmberg C., Åkerborg Ö., Kumar G., Nott D., Kiri S., Sapin C. & Hartz S. (2020). Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. : PharmacoEconomics - open.

Chicago

Schweikert Bernd, Malmberg Chiara, Åkerborg Örjan, Kumar Gayathri, Nott Debby, Kiri Sandeep, Sapin Christophe and Hartz Susanne. 2020. Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. : PharmacoEconomics - open.

Harvard

Schweikert B., Malmberg C., Åkerborg Ö., Kumar G., Nott D., Kiri S., Sapin C. and Hartz S. (2020). Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. : PharmacoEconomics - open.

MLA

Schweikert Bernd, Malmberg Chiara, Åkerborg Örjan, Kumar Gayathri, Nott Debby, Kiri Sandeep, Sapin Christophe and Hartz Susanne. Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. : PharmacoEconomics - open. 2020.